keyword
MENU ▼
Read by QxMD icon Read
search

Peanut immunotherapy

keyword
https://www.readbyqxmd.com/read/29779209/gata3-hypermethylation-and-foxp3-hypomethylation-are-associated-with-sustained-protection-and-bystander-effect-following-epicutaneous-immunotherapy-in-peanut-sensitized-mice
#1
Lucie Mondoulet, Vincent Dioszeghy, Florence Busato, Camille Plaquet, Véronique Dhelft, Kevin Bethune, Laurence Leclere, Christian Daviaud, Mélanie Ligouis, Hugh Sampson, Christophe Dupont, Jörg Tost
BACKGROUND: Epicutaneous immunotherapy (EPIT) is a promising method for treating food allergies. In animal models, EPIT induces sustained unresponsiveness and prevents further sensitization mediated by Tregs. Here, we elucidate the mechanisms underlying the therapeutic effect of EPIT, by characterizing the kinetics of DNA methylation changes in sorted cells from spleen and blood and by evaluating its persistence and bystander effect compared to oral immunotherapy (OIT). METHODS: BALB/c mice orally sensitized to peanut proteins (PPE) were treated by EPIT using a PPE-patch or by PPE-OIT...
May 19, 2018: Allergy
https://www.readbyqxmd.com/read/29754191/the-unique-molecular-signatures-of-contact-dermatitis-and-implications-for-treatment
#2
REVIEW
Alexandra Leonard, Emma Guttman-Yassky
Irritant contact dermatitis (ICD) and allergic contact dermatitis (ACD) are common skin disorders that are characterized by inflammation, oozing, crusting, and pruritus. Atopic dermatitis (AD) is an inflammatory skin disease characterized by immune and barrier abnormalities and is additionally a risk factor for acquiring ICD and ACD. New work on allergic sensitization to common allergens (e.g., nickel and fragrance) in human skin has shown that different allergens have distinct molecular fingerprinting. For example, nickel promotes strong Th1/Th17 polarization, whereas fragrance allergy causes Th2/Th22 skewing, which is similar to the phenotype of AD...
May 12, 2018: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/29700872/oral-immunotherapy-with-omalizumab-reverses-the-th2-cell-like-program-of-regulatory-t-cells-and-restores-their-function
#3
Azza Abdel-Gadir, Lynda Schneider, Arianna Casini, Louis-Marie Charbonnier, Sara V Little, Timothy Harrington, Dale T Umetsu, Rima Rachid, Talal A Chatila
BACKGROUND: Oral immunotherapy (OIT) successfully desensitizes patients with food allergies, but the immune mechanisms mediating its efficacy remain obscure. OBJECTIVES: We tested the hypothesis that allergen-specific regulatory T (Treg) cell function is impaired in food allergy and is restored by anti-IgE antibody (omalizumab)-supplemented OIT. METHODS: Peanut-specific T effector (Teff) and Treg cell proliferative responses, activation markers and cytokine expression were analyzed by flow cytometry in 13 peanut allergic subjects before the start of omalizumab- supplemented OIT and periodically in some subjects thereafter for up to two years...
April 27, 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29700869/tree-nut-allergies-allergen-homology-cross-reactivity-and-implications-for-therapy
#4
Johanna M Smeekens, Kenneth Bagley, Michael Kulis
Tree nut allergy is a potentially life-threatening disease that is increasing in prevalence, now affecting 1% of the general population in the United States. While other food allergies often resolve spontaneously, tree nut allergies are outgrown in less than 10% of cases. Due to the likelihood of cross-sensitization to multiple tree nut allergens, the current treatment guideline is strict avoidance of all nuts once one tree nut allergy has been diagnosed. For example, walnut and pecan are highly cross-reactive, along with cashew and pistachio, but the extent of clinical, IgE-mediated cross-reactivity among other tree nuts remains unclear, therefore making avoidance of all tree nuts a safe approach...
April 27, 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29698554/long-term-outcome-of-peanut-oral-immunotherapy-real-life-experience
#5
Liat Nachshon, Michael R Goldberg, Yitzhak Katz, Michael B Levy, Arnon Elizur
BACKGROUND: Oral immunotherapy (OIT) is currently recommended as a treatment option for peanut allergic patients. Data regarding its long-term compliance and efficacy in real-life is required. METHODS: Peanut allergic patients aged ≥4 years were enrolled in a single-center clinical OIT program. Build-up to 3000 mg peanut protein was performed. Patients reaching this dose before or after 12/2014 were instructed to consume 3000 mg or 1200 mg daily, respectively...
April 26, 2018: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/29680589/peanut-allergens
#6
Chiara Palladino, Heimo Breiteneder
Peanut allergens have the potential to negatively impact on the health and quality of life of millions of consumers worldwide. The seeds of the peanut plant Arachis hypogaea contain an array of allergens that are able to induce the production of specific IgE antibodies in predisposed individuals. A lot of effort has been focused on obtaining the sequences and structures of these allergens due to the high health risk they represent. At present, 16 proteins present in peanuts are officially recognized as allergens...
April 18, 2018: Molecular Immunology
https://www.readbyqxmd.com/read/29665158/peanut-gastro-intestinal-delivery-oral-immunotherapy-in-adolescents-results-of-the-build-up-phase-of-a-randomized-double-blind-placebo-controlled-trial-pita-study
#7
Jean-Luc Fauquert, Elodie Michaud, Bruno Pereira, Lise Bernard, Nelly Gourdon-Dubois, Paul-Olivier Rouzaire, Emmanuelle Rochette, Etienne Merlin, Bertrand Evrard
BACKGROUND: Oral immunotherapy to peanut is effective in desensitizing patients but has significant side effects including anaphylaxis and gastro-intestinal symptoms. In most protocols peanut is administered in a vehicle food. OBJECTIVE: In an exclusively adolescent population, we tested a new approach using sealed capsules of peanut (Gastro-Intestinal Delivery Oral Immunotherapy or GIDOIT) in order to bypass the upper gastro-intestinal tract. The primary aim was to assess the efficacy of the oral build-up phase of GIDOIT and the secondary aim to analyse its safety...
April 17, 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29656306/oral-and-sublingual-immunotherapy-for-treatment-of-ige-mediated-food-allergy
#8
REVIEW
Amy M Scurlock
Development of active therapies for IgE-mediated food allergy is a critical action step toward alleviating the adverse medical, psychosocial, and economic burdens on affected patients and families. Significant progress has been observed specifically in the application of single-allergen oral and sublingual immunotherapy for treatment of IgE-mediated food allergy, with emphasis on milk, egg, and peanut as the primary allergens. Oral immunotherapy (OIT) has demonstrated efficacy in promoting immunomodulatory effects that lead to the clinical outcome of desensitization, defined as reduced reactivity while on active OIT, in the majority of treated individuals; however, achievement of sustained unresponsiveness following cessation of therapy has been observed in a smaller subset of treated subjects...
April 14, 2018: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/29655584/nanoemulsion-adjuvant-driven-redirection-of-t-h-2-immunity-inhibits-allergic-reactions-in-murine-models-of-peanut-allergy
#9
Jessica J O'Konek, Jeffrey J Landers, Katarzyna W Janczak, Rishi R Goel, Anna M Mondrusov, Pamela T Wong, James R Baker
BACKGROUND: Immunotherapy for food allergies involves progressive increased exposures to food that result in desensitization to food allergens in some subjects but not tolerance to the food. Therefore new approaches to suppress allergic immunity to food are necessary. Previously, we demonstrated that intranasal immunization with a nanoemulsion (NE) adjuvant induces robust mucosal antibody and TH 17-polarized immunity, as well as systemic TH 1-biased cellular immunity with suppression of pre-existing TH 2-biased immunity...
April 11, 2018: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29603410/low-dose-oral-immunotherapy-for-children-with-anaphylactic-peanut-allergy-in-japan
#10
Ken-Ichi Nagakura, Noriyuki Yanagida, Sakura Sato, Makoto Nishino, Tomoyuki Asaumi, Kiyotake Ogura, Motohiro Ebisawa
BACKGROUND: Oral immunotherapy (OIT) is a promising treatment for persons with allergy; however, it can also cause adverse allergic reactions. In this study, we investigated the efficacy of low-dose OIT for anaphylactic peanut allergy. METHODS: Twenty-four children (median age, 9.6 years) with anaphylaxis to peanuts were hospitalized for 5 days and then gradually fed increasing amounts of peanut powder up to 133 mg/day. One year later, they underwent an oral food challenge after 2 weeks of peanut avoidance...
March 30, 2018: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/29588872/preventing-peanut-allergy
#11
REVIEW
Meng Chen, Michael Welch, Susan Laubach
The rising prevalence of food allergy and specifically peanut allergy has had significant implications for affected patients, families, and society. The current standard of care remains strict avoidance and the use of emergency medications for accidental ingestions. There is recent evidence-based information to suggest that one approach to preventing peanut allergy lies in early introduction of peanut. This represents a paradigm shift from previous recommendations and has led to updated guidelines in the United States, Europe, and Australasia on the introduction of potentially allergenic foods in the infant diet...
March 1, 2018: Pediatric Allergy, Immunology, and Pulmonology
https://www.readbyqxmd.com/read/29542268/the-effect-of-oral-immunotherapy-treatment-in-severe-ige-mediated-milk-peanut-and-egg-allergy-in-adults
#12
Jarkko Mäntylä, Tuuli Thomander, Auli Hakulinen, Kaarina Kukkonen, Kati Palosuo, Helena Voutilainen, Anna Pelkonen, Paula Kauppi
INTRODUCTION: The standard care of severe food allergy in both adults and children means avoidance of allergens. In recent years promising results of oral immunotherapy (OIT) have been reported in children. In adults, information on OIT in severe food allergy is very limited. OBJECTIVE: We aimed to study if OIT is possible in adults. METHODS: We report OIT results in 10 adult patients with milk OIT, nine adult patients with peanut OIT, and four adult patients with egg OIT...
March 15, 2018: Immunity, Inflammation and Disease
https://www.readbyqxmd.com/read/29524535/advances-in-the-approach-to-the-patient-with-food-allergy
#13
Amy M Scurlock, Stacie M Jones
Advances in food allergy diagnosis, management, prevention, and therapeutic interventions have been significant over the past 2 decades. Evidence-based national and international guidelines have streamlined food allergy diagnosis and management, whereas paradigm-shifting work in primary prevention of peanut allergy has resulted in significant modifications in the approach to early food introduction in infants and toddlers. Innovative investigation of food allergy epidemiology, systems biology, effect, and management has provided important insights...
March 8, 2018: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29470658/current-status-of-potential-therapies-for-ige-mediated-food-allergy
#14
REVIEW
Christopher P Parrish, Daniel Har, J Andrew Bird
PURPOSE OF REVIEW: The goal of this review is to provide the reader with an updated summary of published trial data regarding the use of oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT) for treatment of IgE-mediated food allergies. RECENT FINDINGS: Data from phase 2 trials for treatment of peanut allergy with OIT and EPIT reveal an increase in the threshold of reactivity for peanut-allergic children. Compared to EPIT, OIT promotes a greater increase in the threshold of reactivity; however, adverse events are more common with OIT...
February 22, 2018: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/29444820/a-modified-hypoallergenic-variant-of-the-ricinus-communis-ric-c1-protein-retains-biological-activity
#15
Thaís Pacheco-Soares, André de Oliveira Carvalho, Jucélia da Silva Araújo, Giliane da Silva de Souza, Olga L T Machado
Ric c1, an allergenic protein from Ricinus communis , is an insect α-amylase inhibitor that has become an occupational allergen. Ric c1 can cross-react with allergens from wheat, soybean, peanut, shrimp, fish, gluten, house dust, tobacco, and air fungus, thereby amplifying the concern and risks caused by Ricinus allergens. Two continuous IgE-binding epitopes were identified in Ric c1, both containing glutamic acid residues involved in IgE-binding and allergic challenges. We produced recombinant Ric c1 (rRic c1) in Escherichia coli , using primers from foliar R...
February 14, 2018: Bioscience Reports
https://www.readbyqxmd.com/read/29438186/peanut-allergy-reduction-in-high-risk-pediatric-patients
#16
Jaime Hopper, Courtney Hopp, Jessica Durbin
The prevalence of food allergies has doubled in the past 10 years. Peanut allergies are a significant public health issue and are the primary reason for food-related anaphylactic reactions that result in death. Evidence supports that early introduction of the peanut protein (or in combination with immunotherapy) to the highly allergic may safely desensitize patients, which could lead to less adverse allergic reactions and alter allergy management overall.
March 12, 2018: Nurse Practitioner
https://www.readbyqxmd.com/read/29408715/single-cell-profiling-of-peanut-responsive-t-cells-in-patients-with-peanut-allergy-reveals-heterogeneous-effector-t-h-2-subsets
#17
David Chiang, Xintong Chen, Stacie M Jones, Robert A Wood, Scott H Sicherer, A Wesley Burks, Donald Y M Leung, Charuta Agashe, Alexander Grishin, Peter Dawson, Wendy F Davidson, Leah Newman, Robert Sebra, Miriam Merad, Hugh A Sampson, Bojan Losic, M Cecilia Berin
BACKGROUND: The contribution of phenotypic variation of peanut-specific T cells to clinical allergy or tolerance to peanut is not well understood. OBJECTIVES: Our objective was to comprehensively phenotype peanut-specific T cells in the peripheral blood of subjects with and without peanut allergy (PA). METHODS: We obtained samples from patients with PA, including a cohort undergoing baseline peanut challenges for an immunotherapy trial (Consortium of Food Allergy Research [CoFAR] 6)...
January 31, 2018: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/29369411/safety-and-efficacy-of-epicutaneous-immunotherapy-for-food-allergy
#18
REVIEW
Julie Wang, Hugh A Sampson
Food allergy is increasingly common in children, affecting about 4-8%. The mainstays of management remain allergen avoidance and emergency preparedness to treat allergic reactions with emergency medications. Unfortunately, these approaches are unsatisfactory for many patients and their families as the restrictions, constant vigilance and unpredictable severity of allergic reactions negatively impact quality of life. In recent decades, there has been significant interest in developing treatments for food allergy that lead to desensitization in order to increase thresholds for triggering allergic reactions and decrease the risk of reacting to allergen-contaminated food products...
January 25, 2018: Pediatric Allergy and Immunology
https://www.readbyqxmd.com/read/29339650/oral-immunotherapy-in-japanese-children-with-anaphylactic-peanut-allergy
#19
Ken-Ichi Nagakura, Sakura Sato, Noriyuki Yanagida, Makoto Nishino, Tomoyuki Asaumi, Kiyotake Ogura, Motohiro Ebisawa
BACKGROUND: Reports on oral immunotherapy (OIT) for anaphylactic food allergy are lacking. We investigated the efficacy and safety of peanut OIT for anaphylactic patients. METHODS: We enrolled 22 peanut anaphylactic patients who underwent OIT between 2011 and 2013, all of whom demonstrated anaphylaxis during a baseline double-blind, placebo-controlled food challenge. After starting in-hospital OIT, participants gradually increased ingestion to 795 mg of peanut protein per day at home and then took a maintenance dose (795 mg) daily...
2018: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/29315922/the-use-of-omalizumab-in-allergen-immunotherapy
#20
REVIEW
J A Dantzer, R A Wood
Although omalizumab (anti-IgE) is currently only approved for the treatment of asthma and chronic idiopathic urticaria, it has also been studied as an off-label treatment for numerous allergic conditions, including use as an adjunct to allergen immunotherapy in the treatment of allergic rhinitis, asthma, venom hypersensitivity and food allergy. We conducted a review of publications involving the use of omalizumab with allergen immunotherapy, by searching PubMed with key search terms of "omalizumab" and "immunotherapy...
March 2018: Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology
keyword
keyword
113759
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"